DiscGenics Revenue and Competitors
Estimated Revenue & Valuation
- DiscGenics's estimated annual revenue is currently $6M per year.
- DiscGenics's estimated revenue per employee is $155,000
- DiscGenics's total funding is $68M.
Employee Data
- DiscGenics has 39 Employees.
- DiscGenics grew their employee count by -5% last year.
DiscGenics Competitors & Alternatives
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $7480.2M | 19789 | 5% | N/A | N/A |
What Is DiscGenics?
DiscGenics is a privately held, clinical stage regenerative medicine company focused on developing regenerative therapies that alleviate pain and restore function in patients with degenerative diseases of the spine. DiscGenics is harnessing the restorative potential of cells native to the intervertebral disc to develop what we hope will be a profound therapeutic option for millions of patients suffering from the debilitating effects of back pain. DiscGenicsￃﾢ￢ﾂﾬ￢ﾄﾢ first product candidate, IDCT, is a homologous, allogeneic, injectable cell therapy for the treatment of patients with mild to moderate degenerative disc disease.
keywords:N/A
$68M
Total Funding
39
Number of Employees
$6M
Revenue (est)
-5%
Employee Growth %
N/A
Valuation
N/A
Accelerator
DiscGenics News
Positive interim data that highlighted the safety and efficacy of DiscGenics' cell therapy for degenerative disc disease was the most-read...
SALT LAKE CITY, Sept. 9, 2020 /PRNewswire/ -- DiscGenics, Inc., a clinical stage biopharmaceutical company developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced it has appointed former Medtroni ...
DiscGenics, Inc., a Salt Lake City, UT-based clinical stage biopharmaceutical company developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, raised $50m in Series C funding. The round was led by Ci:z Investment ...
SALT LAKE CITY, Aug. 25, 2020 /PRNewswire/ -- DiscGenics, Inc., a clinical stage biopharmaceutical company developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced it has raised $50 million in a Ser ...
Other Companies in Salt Lake City
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $4.3M | 39 | 875% | $15.9M |
#2 | $4.1M | 39 | 105% | $9.6M |
#3 | $3.9M | 39 | 77% | $6.3M |
#4 | $8.4M | 39 | 105% | N/A |
#5 | $6.7M | 40 | -47% | N/A |
